Priority 8 Sight Loss and Vision PSP Ocular Inflammatory Disease

UNCERTAINTY: What medications best prevent the development of eye disease in Behcets? (JLA PSP Priority 8)
Overall ranking 8
JLA question ID 0014h/8
Explanatory note Relevant reliable up-to-date systematic reviews do not address continuing uncertainties about treatment effects
Evidence None identified
Health Research Classification System category Eye
Extra information provided by this PSP
Original uncertainty examples None provided
Systematic reviews that need updating or extending Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD005556. DOI: 10.1002/14651858.CD005556.pub2
Systematic reviews in preparation (at time of PSP)

None identified

Ongoing controlled trials Evaluation du traitement par corticoth?rapie syst?mique ou par interf?ron alpha2a au cours de la Birdshot r?tinochoro?dopathie compliqu?e d'oedeme maculaire query=eudract_number:2006-003002-26
Submitted by Clinicians
Outcomes to be measured Incidence of Behcets: adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
PSP information
PSP unique ID 0014h
PSP name Sight Loss and Vision - Ocular Inflammatory Disease
Total number of uncertainties identified by this PSP. 108  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop April and May 2013